Fulvestrant (ICI 182,780) Research Workflow

2026-10-01

Build reproducible ERα loss-of-function assays with Fulvestrant (ICI 182,780), from concentration selection and MDM2 tracking to chemotherapy-sensitization studies. The workflow also shows how the compound can serve as a mechanistic control when estrogen signaling is examined alongside immune-cell and endoplasmic-reticulum-stress readouts.

iRGD-RBC Membranes Enhance Neuroblastoma PDT

2026-10-01

This study developed iRGD-functionalized red blood cell membrane vesicles for targeted delivery of the photosensitizer TPOR in neuroblastoma. The biomimetic carrier improved drug release, cellular uptake, apoptosis, migration inhibition, and tumor growth control compared with free TPOR, while also highlighting important translational questions about biodistribution, manufacturing, and photodynamic treatment standardization.

Cyclosporin A: From Structure to Assay Design

2026-09-30

Cyclosporin A connects cyclophilin biology, calcineurin-NFAT signaling, and mitochondrial pore regulation. This guide translates variant-level structural evidence into better assay selection, controls, and interpretation for immunology and mitochondrial research.

2-NBDG Glucose Uptake Assay Kit for HCC

2026-09-30

The 2-NBDG Glucose Uptake Assay Kit provides a rapid, non-radioactive way to connect transporter activity with sorafenib-response phenotypes in hepatocellular carcinoma models. Its single-cell fluorescence readout, PI viability control, and phloretin specificity control help separate altered glucose uptake from cell loss or nonspecific fluorescence.

FPH1: Building a Function-First Liver Platform

2026-09-29

FPH1 (BRD-6125) reframes hepatocyte expansion around function, not cell number alone. This thought-leadership article connects functional proliferation assays and iPSC-derived hepatocyte workflows with emerging, light-regulated gene therapy while clearly separating established evidence from future translational opportunities.

Transient P1 Unwinding in Adenine Riboswitch Binding

2026-09-29

Carbapenemase Gene Transmission in CREC

2026-09-28

Chen et al. examined carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, combining gene detection, plasmid-transfer experiments, susceptibility testing, and strain fingerprinting. The study shows that blaNDM-1 was frequently plasmid-associated and transferable, supporting a surveillance strategy that evaluates resistance genes, mobile elements, phenotype, and clonality together.

Farnesylation-Driven KRAS Condensates in Colon Cancer

2026-09-28

The study proposes that farnesylation at KRAS C185 promotes cytoplasmic condensates that cluster RCE1, support KRAS processing and membrane localization, and amplify tumor-promoting signaling in colon cancer. It also reports that statins, particularly pitavastatin, disrupt this process and can improve response to KRAS G12C inhibition, suggesting a combination strategy that merits further validation.

Lassa Virus Spike: pH-Driven Entry and Inhibitor Action

2026-09-27

Katz and colleagues map pH-induced structural changes in the Lassa virus spike that help explain receptor release and preparation for membrane fusion. Their structural and functional analysis also shows how ARN-75039 inhibits viral entry, providing a mechanistic basis for further study of this investigational inhibitor.

Etoposide (VP-16): Separating DNA Damage from Senescence

2026-09-26

Etoposide (VP-16) is a powerful DNA-damaging research tool, but its effects can be mistaken for senescence or senolysis if assay endpoints are not separated. This guide connects its topoisomerase II mechanism with a Lactobacillus-derived nanovesicle study to show how to design more interpretable experiments.

Açaí Extracts: Hepatocyte Toxicity and DDI Potential

2026-09-25

Raichura and colleagues compared solvent-specific açaí extracts in human hepatocytes and complementary transporter assays, finding extract-dependent, time- and dose-related cytotoxicity but no significant induction of the tested CYP enzymes or transporters. The work highlights why botanical–drug interaction assessment should distinguish cell injury, gene-expression changes, and transporter function rather than treating them as interchangeable measures.

Cholecystokinin octapeptide ammonium in assays

2026-09-25

A practical, evidence-aware guide to using Cholecystokinin octapeptide ammonium (SKU C8717) in cell-response experiments. It covers receptor context, formulation constraints, concentration planning, interpretation of atrial ANP findings, and criteria for selecting a research reagent.

From PXDN to LDHA: Testing GBM Metabolism

2026-09-24

A translational framework for probing the PXDN–LDHA glycolysis axis in glioblastoma, with practical guidance on nucleic-acid perturbation, rescue experiments, and choosing a low-toxicity lipid transfection reagent.

Poly(I:C): TLR3 Agonist for Innate Immunity

2026-09-24

Poly (I:C) is a synthetic double-stranded RNA analog used to stimulate innate immune signaling and interferon responses. Its effects depend on the cell model and delivery route, so it is a research stimulus—not a substitute for viral infection or a universal immune-activation protocol.

CD40–STING–TRAF2 Signaling in ESCC TLS

2026-09-23

A 2025 study links tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma with favorable survival and identifies IRF4-high B cells as a prominent immune feature. Its mechanistic experiments propose that CD40 and STING compete for TRAF2, connecting non-canonical NF-κB signaling with B-cell activation and providing testable directions for biomarker and cancer immunotherapy research.